Substance abuse among patients with treatment-resistant schizophrenia: Characteristics and implications for clozapine therapy

Peter Buckley, Paul Thompson, Lynne Way, Herbert Y. Meltzer

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

Objective: The goals of this study were 1) to determine the extent of substance abuse in patients with treatment-resistant schizophrenia and 2) to assess the relevance of such abuse to subsequent response to treatment with clozapine. Method: The subjects were 118 treatment-resistant patients with DSM-III-R diagnoses of schizophrenia or schizoaffective disorder who underwent detailed demographic, clinical, and psychopathological evaluations before commencing treatment with clozapine. Lifetime and current histories of substance abuse were also systematically evaluated and characterized according to the Research Diagnostic Criteria and DSM-III-R. Response to clozapine treatment at 6 months was determined with measures of psychopathology and psychosocial function. Results: An antecedent or current history of substance abuse was determined for 29 patients. Although predominantly male, the abusers did not differ from the nonabusers on other demographic features. The substance abusers actually showed less psychopathology (negative and disorganization symptoms) and better psychosocial functioning at baseline; however, both groups attained similar improvements on these measures after 6 months of clozapine therapy. Conclusions: A modest extent of previous or current substance abuse was observed among neuroleptic-resistant schizophrenic patients who subsequently received treatment with clozapine. This antecedent history of substance abuse did not appear to negatively influence subsequent response to clozapine treatment.

Original languageEnglish (US)
Pages (from-to)385-389
Number of pages5
JournalAmerican Journal of Psychiatry
Volume151
Issue number3
DOIs
StatePublished - Jan 1 1994

Fingerprint

Clozapine
Substance-Related Disorders
Schizophrenia
Therapeutics
Psychopathology
Diagnostic and Statistical Manual of Mental Disorders
Demography
Psychotic Disorders
Antipsychotic Agents
Research

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Substance abuse among patients with treatment-resistant schizophrenia : Characteristics and implications for clozapine therapy. / Buckley, Peter; Thompson, Paul; Way, Lynne; Meltzer, Herbert Y.

In: American Journal of Psychiatry, Vol. 151, No. 3, 01.01.1994, p. 385-389.

Research output: Contribution to journalArticle

Buckley, Peter ; Thompson, Paul ; Way, Lynne ; Meltzer, Herbert Y. / Substance abuse among patients with treatment-resistant schizophrenia : Characteristics and implications for clozapine therapy. In: American Journal of Psychiatry. 1994 ; Vol. 151, No. 3. pp. 385-389.
@article{5b46fa8e12e94664b722abad256ad33a,
title = "Substance abuse among patients with treatment-resistant schizophrenia: Characteristics and implications for clozapine therapy",
abstract = "Objective: The goals of this study were 1) to determine the extent of substance abuse in patients with treatment-resistant schizophrenia and 2) to assess the relevance of such abuse to subsequent response to treatment with clozapine. Method: The subjects were 118 treatment-resistant patients with DSM-III-R diagnoses of schizophrenia or schizoaffective disorder who underwent detailed demographic, clinical, and psychopathological evaluations before commencing treatment with clozapine. Lifetime and current histories of substance abuse were also systematically evaluated and characterized according to the Research Diagnostic Criteria and DSM-III-R. Response to clozapine treatment at 6 months was determined with measures of psychopathology and psychosocial function. Results: An antecedent or current history of substance abuse was determined for 29 patients. Although predominantly male, the abusers did not differ from the nonabusers on other demographic features. The substance abusers actually showed less psychopathology (negative and disorganization symptoms) and better psychosocial functioning at baseline; however, both groups attained similar improvements on these measures after 6 months of clozapine therapy. Conclusions: A modest extent of previous or current substance abuse was observed among neuroleptic-resistant schizophrenic patients who subsequently received treatment with clozapine. This antecedent history of substance abuse did not appear to negatively influence subsequent response to clozapine treatment.",
author = "Peter Buckley and Paul Thompson and Lynne Way and Meltzer, {Herbert Y.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1176/ajp.151.3.385",
language = "English (US)",
volume = "151",
pages = "385--389",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "3",

}

TY - JOUR

T1 - Substance abuse among patients with treatment-resistant schizophrenia

T2 - Characteristics and implications for clozapine therapy

AU - Buckley, Peter

AU - Thompson, Paul

AU - Way, Lynne

AU - Meltzer, Herbert Y.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Objective: The goals of this study were 1) to determine the extent of substance abuse in patients with treatment-resistant schizophrenia and 2) to assess the relevance of such abuse to subsequent response to treatment with clozapine. Method: The subjects were 118 treatment-resistant patients with DSM-III-R diagnoses of schizophrenia or schizoaffective disorder who underwent detailed demographic, clinical, and psychopathological evaluations before commencing treatment with clozapine. Lifetime and current histories of substance abuse were also systematically evaluated and characterized according to the Research Diagnostic Criteria and DSM-III-R. Response to clozapine treatment at 6 months was determined with measures of psychopathology and psychosocial function. Results: An antecedent or current history of substance abuse was determined for 29 patients. Although predominantly male, the abusers did not differ from the nonabusers on other demographic features. The substance abusers actually showed less psychopathology (negative and disorganization symptoms) and better psychosocial functioning at baseline; however, both groups attained similar improvements on these measures after 6 months of clozapine therapy. Conclusions: A modest extent of previous or current substance abuse was observed among neuroleptic-resistant schizophrenic patients who subsequently received treatment with clozapine. This antecedent history of substance abuse did not appear to negatively influence subsequent response to clozapine treatment.

AB - Objective: The goals of this study were 1) to determine the extent of substance abuse in patients with treatment-resistant schizophrenia and 2) to assess the relevance of such abuse to subsequent response to treatment with clozapine. Method: The subjects were 118 treatment-resistant patients with DSM-III-R diagnoses of schizophrenia or schizoaffective disorder who underwent detailed demographic, clinical, and psychopathological evaluations before commencing treatment with clozapine. Lifetime and current histories of substance abuse were also systematically evaluated and characterized according to the Research Diagnostic Criteria and DSM-III-R. Response to clozapine treatment at 6 months was determined with measures of psychopathology and psychosocial function. Results: An antecedent or current history of substance abuse was determined for 29 patients. Although predominantly male, the abusers did not differ from the nonabusers on other demographic features. The substance abusers actually showed less psychopathology (negative and disorganization symptoms) and better psychosocial functioning at baseline; however, both groups attained similar improvements on these measures after 6 months of clozapine therapy. Conclusions: A modest extent of previous or current substance abuse was observed among neuroleptic-resistant schizophrenic patients who subsequently received treatment with clozapine. This antecedent history of substance abuse did not appear to negatively influence subsequent response to clozapine treatment.

UR - http://www.scopus.com/inward/record.url?scp=0028214584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028214584&partnerID=8YFLogxK

U2 - 10.1176/ajp.151.3.385

DO - 10.1176/ajp.151.3.385

M3 - Article

C2 - 8109646

AN - SCOPUS:0028214584

VL - 151

SP - 385

EP - 389

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 3

ER -